Bausch Health Companies (BHC) – Formerly Valeant (VRX) – 6 reports
See all our reports on Bausch Health Companies.
Kyle Guske II, Senior Investment Analyst, MBA
Valeant
Kyle Guske II, Senior Investment Analyst, MBA
Danger Zone: Rise of the Noise Traders
The noise trader influence is only growing, as the rise of self-directed traders and the relentless noise of the financial press mean the noise to signal ratio is worse than ever.
Sam McBride
Podcast: Why Valeant Was Originally in the Danger Zone
CEO David Trainer sat down with Chuck Jaffe of Money Life to talk about our Danger Zone pick: Valeant (VRX).
Kyle Guske II, Senior Investment Analyst, MBA
ISS Buying EVA Dimensions Signals More Focus on Fundamental Research
Sophisticated investors want metrics that go deeper than reported earnings so they can get a truer picture of cash flows and hold companies accountable for capital allocation.
Sam McBride
Filing Season Finds: Week Of March 4–10
Last week, our analysts parsed 452 filings and collected 58,771 data points. In total, they made 9,978 adjustments with a dollar value of $1.5 trillion. Analyst Hunter Gray made a number of adjustments to Royal Dutch Shell’s (RDS.A) 20-F that caused us to downgrade the stock from Dangerous to Very Dangerous.
Kyle Guske II, Senior Investment Analyst, MBA
ICYMI: Updated Model Portfolios and Valeant’s 10-K Red Flags
Here's what happened at New Constructs this week.
Kyle Guske II, Senior Investment Analyst, MBA
Filing Season Finds: Valeant Pharmaceuticals (VRX)
Analyst Cody Fincher made a total of 44 adjustments to Valeant’s financial statements with a total value of $50 billion. Here are our four largest takeaways from Valeant’s 10-K.
Sam McBride
2016 In Review, Looking Ahead to Next Year
As 2016 comes to an end, we’d like to highlight some of New Constructs’ many accomplishments for this year. We’ve helped our partners and clients avoid stock blow-ups, find long ideas that soar and leverage Model Portfolios that outperform across the board.
Kyle Guske II, Senior Investment Analyst, MBA
What’s The Problem With Non-GAAP Earnings?
Non-GAAP earnings are back in the crosshairs. 15 years after the Enron scandal first prompted the SEC to create rules for non-GAAP metrics, the proliferation of these pro forma results have led to renewed scrutiny.
Sam McBride
Danger Zone: XPO Logistics (XPO)
We’re not talking about Valeant (VRX) or Perrigo (PRGO), or any prior Danger Zone stocks. We’re talking about XPO Logistics (XPO), which looks like another roll up scheme, for the Danger Zone this week.
Kyle Guske II, Senior Investment Analyst, MBA
“Valeant Doesn’t Look Cheap” – Barron’s
Over the weekend, Barron’s magazine featured our research for the fourth time in 2016 and 20th time since 2014. This time, Barron’s featured our research on Valeant Pharmaceuticals (VRX).
Kyle Guske II, Senior Investment Analyst, MBA
Danger Zone: Perrigo Company (PRGO)
We found that Perrigo Company (PRGO), the firm Mr. Papa is leaving behind, exhibits many similarities to Valeant, including misleading non-GAAP measurements, aggressive, shareholder destructive acquisitions, and executive compensation misaligned with shareholders’ interests.
Kyle Guske II, Senior Investment Analyst, MBA
Beware Profiteers Masquerading As Activists
In this special report, we identify and provide specific examples of the red flags you should be on the lookout for when activist investors begin building a large position in a company.
Sam McBride
5 Ways Corporate Governance Affects Investors and Stock Valuations Webinar
In this webinar, David Trainer, a Wall Street veteran, will discuss corporate governance issues to be aware of, how they can affect an investors portfolio, and how they affect underlying stock prices.
Kyle Guske II, Senior Investment Analyst, MBA
David Trainer Covers Why Blackbaud Is In The Danger Zone
CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Blackbaud Inc. (BLKB)
Kyle Guske II, Senior Investment Analyst, MBA
Misaligned Incentives That Led To Valeant Disaster Go Unaddressed
We think that investing in VRX is not a good bet until Valeant’s leadership fully addresses the serious corporate governance flaws that are the source of the problems at the company.
Kyle Guske II, Senior Investment Analyst, MBA
Danger Zone: Compensation Committees
We know that Valeant is not the only company with misaligned executive incentives. There are many others, many of which have already been put in the Danger Zone and some who will go into the Danger Zone soon. This week, however, compensation committees land in the Danger Zone because of the role they play in creating the problems that lead to shareholder value destruction.
Kyle Guske II, Senior Investment Analyst, MBA
Danger Zone: Mondelez International (MDLZ)
This time, we’re talking about Mondelez International (MDLZ), which lands in the Danger Zone this week and looks a lot like VRX.
Kyle Guske II, Senior Investment Analyst, MBA
SumZero Features New Constructs Research
On Tuesday (3/15/16) SumZero prominently featured our research on Valeant Pharmaceuticals (VRX) as the stock dropped over 50% in one day
Kyle Guske II, Senior Investment Analyst, MBA
Today’s 40% Drop Is Not Enough For Valeant Pharmaceuticals
Valeant Pharmaceuticals (VRX: $36/share) had been in a bit of a limbo lately, as investors awaited the long delayed 4Q15 results. The company finally released its earnings today and the results were to be expected if you heeded our previous warnings.
Kyle Guske II, Senior Investment Analyst, MBA